Dioun SM, et al. - Whether pretreatment cardiac evaluation is necessary in patients (n = 235) receiving pegylated liposomal doxorubicin (PLD) for gynecologic cancer was investigated in this study. A median of 3 cycles of PLD were administered to patients with a cumulative dosage of 237 mg over a median observation period of 24 months. Researchers noted that median ejection fraction did not differ significantly, of the 56 patients who had both pre- and post-treatment cardiac testing. The development of PLD-related cardiac toxicity was reported in 3 patients but severe manifestations needing cessation of PLD therapy were noted in only one patient. Findings are suggestive of the possible unnecessity of routine cardiac testing prior to, during or following treatment with PLD. In cases with high clinical suspicion of PLD-related cardiac toxicity, it may be more appropriate to perform cardiac testing.